Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China · Delayed Price · Currency is CNY 16.38
+0.25 (1.55%)
At close: Feb 13, 2026
SHE:300497 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 965.44 | 1,173 | 1,597 | 1,633 | 1,388 | 1,490 |
Other Revenue | 4.88 | 4.88 | 12.39 | 14.28 | 41.15 | 2.64 |
| 970.32 | 1,178 | 1,610 | 1,647 | 1,430 | 1,493 | |
Revenue Growth (YoY) | -25.37% | -26.83% | -2.28% | 15.23% | -4.25% | 10.26% |
Cost of Revenue | 920.6 | 1,124 | 1,471 | 1,433 | 996.18 | 892.31 |
Gross Profit | 49.72 | 53.88 | 138.32 | 214.38 | 433.36 | 600.64 |
Selling, General & Admin | 148.38 | 152.9 | 193.55 | 179.91 | 163.47 | 121.47 |
Research & Development | 63.88 | 74.66 | 97.45 | 77.45 | 78.51 | 76.53 |
Other Operating Expenses | 23.66 | 16.59 | 16.53 | 15.23 | 14.58 | 14.96 |
Operating Expenses | 231.23 | 243.27 | 308.44 | 273.38 | 260.29 | 216.3 |
Operating Income | -181.51 | -189.4 | -170.12 | -59 | 173.07 | 384.34 |
Interest Expense | -39.85 | -40.58 | -42.03 | -41.1 | -24.92 | -23.74 |
Interest & Investment Income | 5.71 | 6.68 | 9.29 | 23.29 | 16.4 | 14.68 |
Currency Exchange Gain (Loss) | 8.29 | 8.29 | 7.9 | 18.81 | -3.81 | -18.75 |
Other Non Operating Income (Expenses) | -6.12 | -2.48 | -4.54 | -3.51 | -0.21 | -0.7 |
EBT Excluding Unusual Items | -213.47 | -217.49 | -199.5 | -61.5 | 160.53 | 355.83 |
Impairment of Goodwill | - | - | -1.15 | -1.07 | - | - |
Gain (Loss) on Sale of Investments | -13.85 | -13.99 | -15.5 | -82.93 | -131.99 | -15.56 |
Gain (Loss) on Sale of Assets | -1.2 | -0.1 | 0.08 | 0.41 | -0.06 | 1.02 |
Asset Writedown | -103.98 | -101.63 | -23.74 | -12.82 | -2.01 | -9.16 |
Other Unusual Items | 45.46 | 44.65 | 6.64 | 15.21 | 28.61 | 46.69 |
Pretax Income | -287.04 | -288.56 | -233.17 | -142.71 | 55.07 | 378.81 |
Income Tax Expense | -8.11 | -8.11 | -9.91 | 21.47 | 15.53 | 56.63 |
Earnings From Continuing Operations | -278.93 | -280.45 | -223.26 | -164.17 | 39.54 | 322.18 |
Minority Interest in Earnings | 6.15 | 8.35 | 22.46 | 22.7 | 9.29 | -2.88 |
Net Income | -272.78 | -272.1 | -200.8 | -141.47 | 48.83 | 319.3 |
Net Income to Common | -272.78 | -272.1 | -200.8 | -141.47 | 48.83 | 319.3 |
Net Income Growth | - | - | - | - | -84.71% | 4.40% |
Shares Outstanding (Basic) | 538 | 534 | 543 | 544 | 543 | 456 |
Shares Outstanding (Diluted) | 538 | 534 | 543 | 544 | 543 | 463 |
Shares Change (YoY) | 2.92% | -1.69% | -0.26% | 0.29% | 17.25% | 1.38% |
EPS (Basic) | -0.51 | -0.51 | -0.37 | -0.26 | 0.09 | 0.70 |
EPS (Diluted) | -0.51 | -0.51 | -0.37 | -0.26 | 0.09 | 0.69 |
EPS Growth | - | - | - | - | -86.96% | 2.99% |
Free Cash Flow | -146.02 | 45.89 | -306.99 | -580.26 | -607.28 | -66.89 |
Free Cash Flow Per Share | -0.27 | 0.09 | -0.57 | -1.07 | -1.12 | -0.14 |
Dividend Per Share | - | - | - | - | - | 0.200 |
Dividend Growth | - | - | - | - | - | 60.00% |
Gross Margin | 5.12% | 4.57% | 8.59% | 13.01% | 30.31% | 40.23% |
Operating Margin | -18.71% | -16.08% | -10.57% | -3.58% | 12.11% | 25.74% |
Profit Margin | -28.11% | -23.10% | -12.47% | -8.59% | 3.42% | 21.39% |
Free Cash Flow Margin | -15.05% | 3.90% | -19.07% | -35.23% | -42.48% | -4.48% |
EBITDA | -2.35 | -18.68 | -10.66 | 64.84 | 271.64 | 458.28 |
EBITDA Margin | -0.24% | -1.59% | -0.66% | 3.94% | 19.00% | 30.70% |
D&A For EBITDA | 179.16 | 170.72 | 159.46 | 123.84 | 98.57 | 73.93 |
EBIT | -181.51 | -189.4 | -170.12 | -59 | 173.07 | 384.34 |
EBIT Margin | -18.71% | -16.08% | -10.57% | -3.58% | 12.11% | 25.74% |
Effective Tax Rate | - | - | - | - | 28.20% | 14.95% |
Revenue as Reported | 970.32 | 1,178 | 1,610 | 1,647 | 1,430 | 1,493 |
Advertising Expenses | - | 4.05 | 6.19 | - | 4.19 | 3.25 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.